1. Search Result
Search Result
Results for "

acute respiratory syndrome

" in MedChemExpress (MCE) Product Catalog:

40

Inhibitors & Agonists

1

Fluorescent Dye

2

Peptides

4

Inhibitory Antibodies

4

Natural
Products

18

Recombinant Proteins

2

Click Chemistry

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-150735

    IRAK Inflammation/Immunology
    IRAK4-IN-20 (Compound BAY-1834845) is an orally active IRAK4 inhibitor with an IC50 of 3.55 nM. IRAK4-IN-20 can be used for acute respiratory distress syndrome (ARDS) research .
    IRAK4-IN-20
  • HY-P99810

    AVTX-002; AEVI 002; SAR 252067; CERC-002; MDGN-002

    SARS-CoV Cardiovascular Disease
    Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) that plays an important role in acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) COVID-19. Quisovalimab can be used in COVID-19 acute respiratory distress syndrome and other studies .
    Quisovalimab
  • HY-P991401

    TNF Receptor Inflammation/Immunology
    GSK2862277 is a human monoclonal antibody (mAb) targeting TNFRSF1A. GSK2862277 increases neutrophil extracellular trap formation and alveolar macrophage phagocytosis. GSK2862277 can be used in Acute lung injury and Acute Respiratory Distress Syndrome (ARDS) research. Recommended isotype control: VHH-hFc .
    GSK2862277
  • HY-159159

    NOD-like Receptor (NLR) Inflammation/Immunology
    MS-II-124 is an effective and selective NLRP3 inhibitor (IC50=0.12 μM) with anti-inflammatory and immunomodulatory activities, which can be used in the research of acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) .
    MS-II-124
  • HY-159131

    Histone Acetyltransferase Epigenetic Reader Domain Inflammation/Immunology
    PNSC928 is an inhibitor for the CtBP2-p300 interaction with an IC50 of 23.60 µM, and reverses the Lipopolysaccharides (HY-D1056)-induced expressions of proinflammatory cytokines in RAW264.7. PNSC928 ameliorates the acute respiratory distress syndrome (ARDS)in mice .
    PNSC928
  • HY-W423489

    S-Adenosyl-DL-homocysteine

    SARS-CoV Infection
    SARS-CoV-2-IN-76 (compound 1) is a nsp14-viral cap N7 methyltranferase and PLpro inhibitor of severe acute respiratory syndrome corona virus (SARS-CoV-2) .
    SARS-CoV-2-IN-76
  • HY-P10889

    Phosphatase Inflammation/Immunology
    CNI103 is a highly potent and metabolically stable cell-permeable peptide inhibitor of calcineurin. CNI103 selectively blocks the interaction between calcineurin and NFATc3 (KD=16 nM), thereby preventing NFATc3 activation in vitro and in vivo. CNI103 can be used to study acute respiratory distress syndrome (ARDS) and other inflammatory diseases .
    CNI103
  • HY-149267

    STING SARS-CoV Infection
    STING agonist-30 is a potent STING agonist. STING agonist-30 exhibits STING-dependent immune activation. STING agonist-30 has extensive inhibitory effects on various viruses, including the herpes simplex virus (HSV), rotavirus, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .
    STING agonist-30
  • HY-P991400

    TNF Receptor Inflammation/Immunology
    GSK1995057 is a human monoclonal antibody (mAb) targeting TNFRSF1A. GSK1995057 attenuates pulmonary neutrophilia, inflammatory cytokine release and signs of endothelial injury in bronchoalveolar lavage and serum samples. GSK1995057 can be used in Acute lung injury and Adult respiratory distress syndrome research. Recommended isotype control: dAb (VHH-His) .
    GSK1995057
  • HY-P2296

    Fluorescent Dye Others
    Abz-FRLKGGAPIKGV-EDDNP TFA is a fluorogenic substrate used to measure the enzymatic activities of protease forms, such as papain-like protease 2 (PLP2) from severe acute respiratory syndrome coronavirus (SARS-CoV). Abz-FRLKGGAPIKGV-EDDNP TFA has the potential for study 2019-nCoV (COVID-19) infection .
    Abz-FRLKGGAPIKGV-EDDNP TFA
  • HY-117043
    GRL0617
    10+ Cited Publications

    Deubiquitinase SARS-CoV Infection
    GRL0617 is a selective and competitive noncovalent inhibitor of severe acute respiratory syndrome (SARS-CoV) papain-like protease (PLpro), with an IC50 of 0.6 μM and a Ki value of 0.49 μM. GRL0617 also inhibits SARS-CoV with an EC50 of 14.5 μM. GRL0617 can be used for the research of severe acute respiratory syndrome .
    GRL0617
  • HY-116462

    Drug Metabolite Others
    ONO-EI-601 is the major metabolite of human neutrophil elastase inhibitor ONO-5046. ONO-5046 has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19 .
    ONO-EI-601
  • HY-17443
    Sivelestat
    Maximum Cited Publications
    21 Publications Verification

    EI546; LY544349; ONO5046

    Elastase SARS-CoV Cancer
    Sivelestat (EI546) is a competitive inhibitor of human neutrophil elastase, with an IC50 of 44 nM and a Ki of 200 nM. Sivelestat (EI546) has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19 .
    Sivelestat
  • HY-17443A
    Sivelestat sodium
    Maximum Cited Publications
    21 Publications Verification

    ONO5046-Na; Sodium sivelestat; EI546 sodium; LY544349 sodium

    Elastase SARS-CoV Cancer
    Sivelestat (EI546) sodium is a competitive inhibitor of human neutrophil elastase, with an IC50 of 44 nM and a Ki of 200 nM. Sivelestat (EI546) sodium has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19 .
    Sivelestat sodium
  • HY-145390

    Keap1-Nrf2 Inflammation/Immunology
    Nrf2 activator-1 is a potent activator of NF-E2 related factor 2 (Nrf2). Nrf2 activator-1 has the potential for the research of COPD and other respiratory diseases, including asthma, Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS) and pulmonary fibrosis (extracted from patent WO2018109647A1) .
    Nrf2 activator-1
  • HY-P99889

    BRII-198

    SARS-CoV Infection
    Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .
    Romlusevimab
  • HY-17443B
    Sivelestat sodium tetrahydrate
    Maximum Cited Publications
    21 Publications Verification

    EI546 sodium tetrahydrate; LY544349 sodium tetrahydrate; ONO5046 sodium tetrahydrate

    Elastase SARS-CoV Cancer
    Sivelestat (EI546) sodium tetrahydrate is a competitive inhibitor of human neutrophil elastase, with an IC50 of 44 nM and a Ki of 200 nM. Sivelestat (EI546) sodium tetrahydrate has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19 .
    Sivelestat sodium tetrahydrate
  • HY-N1910
    4'-O-Methylbavachalcone
    1 Publications Verification

    SARS-CoV Infection
    4'-O-Methylbavachalcone is a chalcone isolated from Psoralea corylifolia, inhibits severe acute respiratory syndrome coronavirus (SARS-CoV) papain-like protease (PLpro) activity, with an IC50 of 10.1 μM .
    4'-O-Methylbavachalcone
  • HY-N13798

    NF-κB Biochemical Assay Reagents Inflammation/Immunology
    ADHPE is a stabilizer of 14-3-3σ and p65 protein complex. ADHPE inhibits NF-κB (p65) signaling pathway and reduces the inflammatory response. ADHPE can be used for pediatric pneumonia-related acute lung injury and acute respiratory distress syndrome study .
    ADHPE
  • HY-151232

    PRN1008

    Btk Inflammation/Immunology
    Rilzabrutinib (PRN1008) is an orally active Bruton's tyrosine kinase (BTK) inhibitor with anti-inflammatory and immunomodulatory activities. Rilzabrutinib can be used in the research of various inflammatory and immune-related diseases such as acute respiratory distress syndrome and sepsis .
    Rilzabrutinib
  • HY-145390A

    Keap1-Nrf2 Inflammation/Immunology
    (R,R)-Nrf2 activator-1 is the enantiomer of Nrf2 activator-1. Nrf2 activator-1 is a potent activator of NF-E2 related factor 2 (Nrf2). Nrf2 activator-1 has the potential for the research of COPD and other respiratory diseases, including asthma, Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS) and pulmonary fibrosis .
    (R,R)-Nrf2 activator-1
  • HY-138067

    SARS-CoV Inflammation/Immunology
    SSAA09E2 is an inhibitor of SARS-CoV (Severe acute respiratory syndrome-Coronavirus) replication, acting by blocking early interactions of SARS-S with the receptor for SARS-CoV, Angiotensin Converting Enzyme-2 (ACE2) .
    SSAA09E2
  • HY-17443BR

    Elastase SARS-CoV Cancer
    Sivelestat (sodium tetrahydrate) (Standard) is the analytical standard of Sivelestat (sodium tetrahydrate). This product is intended for research and analytical applications. Sivelestat (EI546) sodium tetrahydrate is a competitive inhibitor of human neutrophil elastase, with an IC50 of 44 nM and a Ki of 200 nM. Sivelestat (EI546) sodium tetrahydrate has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19 .
    Sivelestat (sodium tetrahydrate) (Standard)
  • HY-122668

    SARS-CoV Infection
    K22 is an inhibitor of coronavirus RNA synthesis that specifically targets membrane-associated coronavirus RNA synthesis. K22 effectively blocks replication of multiple coronaviruses by inhibiting the critical step of viral replication complex anchoring to host cell membranes to form double-membrane vesicles (DMVs). K22 exhibits broad-spectrum antiviral activity against diverse coronaviruses, including Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Feline Coronavirus (FCoV), Mouse Hepatitis Virus (MHV), and Avian Infectious Bronchitis Virus (IBV) .
    K22
  • HY-162701

    SARS-CoV Influenza Virus RSV HSV Infection
    Antiviral agent 58 (Compound J1) is an orally active antiviral agent with broad-spectrum antiviral activity against enveloped viruses, including influenza A virus (IAV), respiratory syncytial virus (RSV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), human coronavirus OC43 (HCoV-OC43), herpes simplex virus type 1 (HSV-1), and HSV-2 .
    Antiviral agent 58
  • HY-160554

    Liposome Infection Inflammation/Immunology
    C12-113 is a lipidoid delivery agent that can be used to transfect siRNA into cells. C12-113 can also be combined with other lipids to form lipid nanoparticles (LNPs) for the delivery of mRNA encoding the spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in mice .
    C12-113
  • HY-W024485

    SARS-CoV Infection
    SARS-CoV-2-IN-86 (Compound 2734589) is a dual inhibitor of the methyltransferases nsp14 and nsp16 of SARS-CoV-2. SARS-CoV-2-IN-86 exhibits low toxicity with a LD50 of 700 mg/kg according to toxicity analysis predict .
    SARS-CoV-2-IN-86
  • HY-100943
    Cinanserin hydrochloride
    1 Publications Verification

    SQ 10643

    5-HT Receptor Influenza Virus Infection Inflammation/Immunology
    Cinanserin hydrochloride (SQ 10643) is a potent, selective and highly affinity 5-HT2 receptor antagonist with a Ki of 41 nM. Cinanserin hydrochloride has a much higher binding affinity for the 5-HT2 than for the 5-HT1 receptor (Ki of 3500 nM). Cinanserin is also an inhibitor of 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro .
    Cinanserin hydrochloride
  • HY-168568

    SARS-CoV Infection
    SARS-CoV-2 Mpro-IN-28 (Compound 1K) is an inhibitor of SARS-CoV-2 M pro with an EC50 value of 24 μM .
    SARS-CoV-2 Mpro-IN-28
  • HY-168564

    SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-27 (Compound 9H) is an inhibitor of SARS-CoV-2 3CL pro with an IC50 value of 21 nM. SARS-CoV-2 3CLpro-IN-27 exhibits excellent anti-SARS-CoV-2 replicon activity, demonstrating an EC50 value of 5 nM .
    SARS-CoV-2 3CLpro-IN-27
  • HY-139111

    Cathepsin SARS-CoV Infection
    Oxocarbazate is an inhibitor of human cathepsin L with the IC50 values of 6.9 nM (human Cathepsin L,0 h) 0.4 nM ((human Cathepsin L,4 h) and 5.07 μM (human cathepsin B), respectively. Oxocarbazate blockes both SARS-CoV (IC50 = 273 nM) and Ebola virus (IC50 = 193 nM) entry into 293T cells .
    Oxocarbazate
  • HY-168600

    SARS-CoV Infection
    SARS-CoV-2 Mpro-IN-32 (Compound 1) is a selective inhibitor of SARS-CoV-2 M Pro with an IC50 value of 230 nM. SARS-CoV-2 Mpro-IN-32 can also inhibit the replication of multiple SARS-CoV-2 variants in vitro .
    SARS-CoV-2 Mpro-IN-32
  • HY-168599

    SARS-CoV Infection
    SARS-CoV-2 Mpro-IN-31 (Compound 18) is an inhibitor of SARS-CoV-2 M Pro with an IC50 value of 11 nM. Additionally, SARS-CoV-2 Mpro-IN-31 effectively inhibits the enzymatic activity of the cysteine proteases cathepsin B and cathepsin L, with IC50 values of 24 nM and 1.8 nM, respectively .
    SARS-CoV-2 Mpro-IN-31
  • HY-D2342

    Fluorescent Dye Infection
    SARS-CoV-2 3CLpro probe-1 (Compound probe 3) is a selective and activity-based probe for the SARS-CoV-2 3CL protease. SARS-CoV-2 3CLpro probe-1 can detect endogenously expressed 3CLpro in SARS-CoV-2-infected cells .
    SARS-CoV-2 3CLpro probe-1
  • HY-157477

    SARS-CoV Cathepsin Infection
    SARS-CoV-2 3CLpro-IN-22 (Compound 17) is a cathepsin L (CTSL ) inhibitor with an IC50 value of 32.5 nM. SARS-CoV-2 3CLpro-IN-22 can be used for the study of SARS-CoV-2 virus .
    SARS-CoV-2 3CLpro-IN-22
  • HY-149052

    RIP kinase Mixed Lineage Kinase Necroptosis Inflammation/Immunology
    SZM-1209 is an orally active, potent and specific RIPK1 inhibitor, with a Kd of 85 nM. SZM-1209 exhibits high anti-necroptotic activity (EC50=22.4 ± 8.1 nM). SZM-1209 shows anti-SIRS (systemic inflammatory response syndrome), and anti-ALI (acute lung injury) effects .
    SZM-1209
  • HY-152005

    SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-6 is a reversible covalent inhibitor of SARS-CoV-2 3CL protease. SARS-CoV-2 3CLpro-IN-6 has potent inhibitory activity for SARS-CoV-2 3CL pro with an IC50 value of 4.9 μM. SARS-CoV-2 3CLpro-IN-6 can be used for the research of coronavirus disease 2019 (COVID-19) .
    SARS-CoV-2 3CLpro-IN-6
  • HY-N6972
    Cepharanthine
    5+ Cited Publications

    Autophagy SARS-CoV Cytochrome P450 Apoptosis Parasite Infection Inflammation/Immunology Cancer
    Cepharanthine is a natural product that can be isolated from the plant Stephania cephalantha Hayata. Cepharanthine has anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) activities. Cepharanthine has good effective in suppressing viral proliferation (half maximal (50%) inhibitory concentration (IC50) and 90% inhibitory concentration (IC90) values of 1.90 and 4.46 μM . Cepharanthine can also effectively reverses P-gp-mediated multidrug resistance in K562 cells and increase enhances the sensitivity of anticancer agents in xenograft mice model . Cepharanthine shows inhibitory effects of human liver cytochrome P450 enzymes CYP3A4, CYP2E1 and CYP2C9. Cepharanthine has antitumor, anti-inflammatory and antinociceptive effects .
    Cepharanthine
  • HY-N6972R

    Autophagy SARS-CoV Cytochrome P450 Apoptosis Parasite Infection Inflammation/Immunology Cancer
    Cepharanthine (Standard) is the analytical standard of Cepharanthine. This product is intended for research and analytical applications. Cepharanthine is a natural product that can be isolated from the plant Stephania?cephalantha?Hayata. Cepharanthine has anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) activities. Cepharanthine has good effective in suppressing viral proliferation (half maximal (50%) inhibitory concentration (IC50) and 90% inhibitory concentration (IC90) values of 1.90 and 4.46?μM . Cepharanthine can also effectively reverses P-gp-mediated multidrug resistance in K562 cells and increase enhances the sensitivity of anticancer agents in xenograft mice model . Cepharanthine shows inhibitory effects of human liver cytochrome P450 enzymes CYP3A4, CYP2E1 and CYP2C9. Cepharanthine has antitumor, anti-inflammatory and antinociceptive effects .
    Cepharanthine (Standard)
  • HY-151535

    SARS-CoV Infection Inflammation/Immunology
    SARS-CoV-2 3CLpro-IN-5 is a covalent inhibitor of 3C-like protease (3CL pro). SARS-CoV-2 3CLpro-IN-5 has inhibitory activity for 3CL pro with an IC50 value of 3.8 nM. SARS-CoV-2 3CLpro-IN-5 has 9.0% oral bioavailability (BA). SARS-CoV-2 3CLpro-IN-5 can be used for the research of coronavirus disease 2019 (COVID-19) .
    SARS-CoV-2 3CLpro-IN-5

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: